September 26, 2016

Corvus Pharmaceuticals Announces Preclinical and Preliminary Clinical Biomarker Data of Lead Oral Checkpoint Inhibitor CPI-444 Presented at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

  • Preclinical Studies Demonstrate Activity of CPI-444 Both Alone and in Combination with Anti-PD-1 and Anti-PD-L1 Antibodies

  • Preliminary Phase 1/1b Clinical Biomarker Data Show Complete Blockade of peripheral Blood Lymphocyte A2A Receptors in Dose-Dependent Manner and Induction of Activated T-Cells

BURLINGAME, Calif., Sept. 25, 2016 (GLOBE NEWSWIRE)

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced preclinical data as well as preliminary biomarker data from its ongoing Phase 1/1b study of CPI-444 as a single agent and in combination with Genentech’s TECENTRIQ™ (atezolizumab), a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1). CPI-444 is a selective and potent inhibitor of the
adenosine A2A receptor. The data were presented today in both oral and poster
presentations by Stephen Willingham, Ph.D., Corvus senior scientist, at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, which is taking place in New York at the Sheraton New York Times Square Hotel and the New York Hilton Midtown.